About

OKYO Pharma Ltd. (NASDAQ:OKYO), is a biopharmaceutical company dedicated to developing an innovative treatment for neuropathic corneal pain and dry eye disease. Through its proprietary chemerin peptide, OK-101, the company aims to provide targeted therapy that not only alleviates pain but also controls inflammation, while enhancing ocular residence time for more effective, lasting relief.